



ASX Release

Anatara Annual General Meeting Results

MELBOURNE, 16 November 2021: Anatara Lifesciences (ASX: ANR), is pleased to announce the following results from the Annual General Meeting held on 16 November 2021.

At today's Annual General Meeting all Resolutions put to Shareholders were passed on a poll. Details of the Proxy Votes are attached.

STEPHEN DENARO
COMPANY SECRETARY

This announcement is authorised by the Board, Anatara Lifesciences Limited.

For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anatara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatara.com	Eric Kuret Market Eye +61 (0) 417 311 335 eric.kuret@marketeye.com.au

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based solutions for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for human and animal health considerations. Anatara is focused on building a portfolio of human gastrointestinal health products, with lead product GaRP (Gastrointestinal ReProgramming) being a dietary supplement with a range of potential indications for the relief of gastrointestinal tract (GIT) symptoms and conditions. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

Suite 101, 55 Flemington Rd, North Melbourne, VIC 3051, Australia

Email info@anatara.com | Website anataralifesciences.com



ANATARA LIFESCIENCES LIMITED
2021 Annual General Meeting
Tuesday, 16 November 2021
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	15,771,688 92.56%	171,301 1.01%	1,096,162 6.43%	112,632	17,387,850 97.35%	473,694 2.65%	112,632	Carried
2 Re-election of Ms Sue MacLeman	Ordinary	17,175,550 93.14%	174,389 0.95%	1,091,162 5.91%	42,998	19,089,105 99.09%	174,389 0.91%	42,998	Carried
3 Issue of Director Options to a Related Party - Ms Sue MacLeman	Ordinary	15,565,896 84.44%	1,780,043 9.65%	1,091,162 5.91%	46,998	17,177,058 89.19%	2,082,436 10.81%	46,998	Carried
4 Issue of Director Options to a Related Party - Dr Jane Ryan	Ordinary	15,382,818 84.27%	1,780,043 9.75%	1,091,162 5.98%	230,076	16,993,980 89.08%	2,082,436 10.92%	230,076	Carried
5 Issue of Director Options to a Related Party - Dr David Brookes	Ordinary	15,265,896 84.17%	1,780,043 9.81%	1,091,162 6.02%	346,998	16,877,058 89.02%	2,082,436 10.98%	346,998	Carried
6 Approval of 10% Placement Facility	Special	16,781,657 90.85%	601,280 3.25%	1,091,162 5.90%	10,000	19,195,212 99.48%	101,280 0.52%	10,000	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.